FEMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FEMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Femasys's yield on cost for the quarter that ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Femasys's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Medical Instruments & Supplies subindustry, Femasys's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Femasys's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Femasys is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Femasys (NAS:FEMY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Femasys's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith J Kendall | director | 30 TECHNOLOGY DRIVE, WARREN NJ 07059 |
Alistair Milnes | director | C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Christine E Thomas | officer: SVP, Regulatory & Clinical | 2836 SW 117TH STREET, GAINESVILLE FL 32606 |
Dov Elefant | officer: Chief Financial Officer | EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632 |
Wendy Perrow | director | C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906 |
Edward Evantash | officer: Chief Medical Officer | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024 |
John Dyett | director, 10 percent owner | 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025 |
Adams John Q Jr | director | 35 WYCK HILL LANE, WESTLAKE TX 76262 |
Edward R Uzialko | director, 10 percent owner | 4605 DUDLEY LANE, ATLANTA GA 30327 |
Charles Larsen | director | 28 SANDPIPER ROAD, TAMPA FL 33609 |
Kathy Lee-sepsick | director, officer: Chief Executive Officer | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024 |
Daniel Scott Currie | officer: Senior VP, Operations | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024 |
Kelley Hoskin Violet Alexandria | officer: VP, Clinical & Medical Affairs | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024 |
Gary Thompson | director | 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024 |
William Benson Witte | director | 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025 |
From GuruFocus
By Marketwired • 08-29-2024
By Marketwired • 11-26-2024
By Marketwired • 11-01-2024
By Marketwired • 06-27-2024
By Marketwired • 10-02-2024
By Marketwired • 09-09-2024
By PRNewswire • 10-13-2023
By Marketwired • 10-08-2024
By Marketwired • 10-11-2023
By Marketwired • 11-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.